Isomorphic Labs raises $5bn to move its AI-designed medicines towards clinical trials
The London drug discovery company, led by Sir Demis Hassabis, says its cancer and immunology programmes have produced positive preclinical results, and the money will help it build clinical development capacity.
By Daily Oracles News Team1 min read
Isomorphic Labs has raised $5bn to take the medicines it designs with artificial intelligence towards their first tests in people.
The Series C round, announced on Tuesday, was co-led by Greenoaks and Sequoia Capital. Andreessen Horowitz and several other new backers joined, Alphabet invested again, and every existing investor took part: Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund.
Isomorphic was founded in 2021 and is based in London, with offices in Cambridge, Massachusetts, and Lausanne in Switzerland. Sir Demis Hassabis is chief executive and Max Jaderberg president. Its main tool is a drug design engine it calls IsoDDE, a set of AI models that simulate how molecules behave so that its scientists can design and refine candidate drugs across different diseases and types of medicine.
What the money is for
The company said that work is producing positive preclinical results, both in its own oncology and immunology programmes and in projects with partners. None of its candidates has yet entered clinical trials. The new funding will pay for:
- further development of IsoDDE and models covering new areas of biology
- a network of partners working on the biology of disease
- global infrastructure for AI-led bioengineering
- translational and clinical development capacity as candidates move into trials
The Sovereign AI Fund also backed the AI chip start-up Fractile in its fundraising of more than £500m earlier this month.




